Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.78 USD | +9.45% | -1.94% | +107.46% |
Mar. 20 | Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024 | |
Mar. 20 | Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Evolution of the average Target Price on Trevi Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Trevi Therapeutics, Inc.
B. Riley | |
JonesTrading Institutional Services | |
SVB Securities LLC | |
Oppenheimer | |
Needham & Co. | |
Aegis Capital |
EPS Revisions
- Stock Market
- Equities
- TRVI Stock
- Consensus Trevi Therapeutics, Inc.